E2Z Stock Overview
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. More details
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 1/6 |
Almirall, S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €8.35 |
| 52 Week High | €9.96 |
| 52 Week Low | €7.79 |
| Beta | 0.36 |
| 11 Month Change | -8.64% |
| 3 Month Change | -5.54% |
| 1 Year Change | -2.34% |
| 33 Year Change | -21.30% |
| 5 Year Change | -42.53% |
| Change since IPO | -42.61% |
Recent News & Updates
Recent updates
Shareholder Returns
| E2Z | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -4.5% | -10.1% | -1.5% |
| 1Y | -2.3% | -21.6% | 7.9% |
Return vs Industry: E2Z exceeded the German Pharmaceuticals industry which returned -24.1% over the past year.
Return vs Market: E2Z underperformed the German Market which returned 8.3% over the past year.
Price Volatility
| E2Z volatility | |
|---|---|
| E2Z Average Weekly Movement | 2.6% |
| Pharmaceuticals Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: E2Z has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: E2Z's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1943 | 1,996 | Carlos Gallardo Piqué | www.almirall.com |
Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer.
Almirall, S.A. Fundamentals Summary
| E2Z fundamental statistics | |
|---|---|
| Market cap | €1.79b |
| Earnings (TTM) | -€44.87m |
| Revenue (TTM) | €953.49m |
1.9x
P/S Ratio-40.0x
P/E RatioIs E2Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| E2Z income statement (TTM) | |
|---|---|
| Revenue | €953.49m |
| Cost of Revenue | €255.10m |
| Gross Profit | €698.39m |
| Other Expenses | €743.26m |
| Earnings | -€44.87m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 73.25% |
| Net Profit Margin | -4.71% |
| Debt/Equity Ratio | 23.6% |
How did E2Z perform over the long term?
See historical performance and comparison